Neuroscience News and Research

RSS

AstraZeneca provides free medicines to patients at Primary Care Center Pharmacy in Sacramento

AstraZeneca announced today that it is providing medicines at no cost to qualifying patients at the Primary Care Center Pharmacy in Sacramento, California.

7 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

New video PSA may help raise donation for brain research

In its continuing fight to end brain disorders, the American Academy of Neurology Foundation is turning entries submitted to the 2010 Neuro Film Festival into its latest video public service announcement about the need for donations for more research into curing brain disorders.

7 Oct 2010

Herbal supplements can treat anxiety disorders

A systematic review of research into the use of nutritional supplements for the treatment of anxiety disorders has found strong evidence for the use of extracts of passionflower or kava and combinations of L-lysine and L-arginine. Researchers writing in BioMed Central's open access Nutrition Journal pooled the results of 24 studies involving a total of more than 2000 participants, showing that some nutritional and herbal supplements can be effective, without the risk of serious side effects.

7 Oct 2010

Lumosity.com launches Italian version of cognitive training service

Lumosity.com, the leading online provider of games that improve brain performance, announced today the launch of an Italian version of their cognitive training service -- i.lumosity.com/it. The translation of the site into Italian was sponsored by Abbott Laboratories. Abbott also sponsored hundreds of memberships to make the Lumosity.com cognitive training program available to doctors and patients throughout Italy in an effort to raise awareness about the cognitive deficits associated with HIV/AIDS.

6 Oct 2010

NBF's Brilliance in Bipolar Initiative receives Congressman Kennedy's endorsement

Congressman Patrick Kennedy, a long-time advocate for people living with mental illness, and Marc Kullman, co-founder of the National Bipolar Foundation, joined efforts to help reduce the stigma associated with bipolar disorder. The Brilliance in Bipolar Initiative is a national and collaborative effort to draw attention to and develop a better understanding of bipolar disorder.

6 Oct 2010

New hope for patients with brain injury

New neuroscience research by life scientists from UCLA and Australia may potentially help people who have lost their ability to remember due to brain injury or disease.

6 Oct 2010

Study may lend insight about hallucination mechanism in schizophrenia

Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.

6 Oct 2010

Elsevier launches new version of BrainNavigator online research tool

Elsevier, the leading publisher of scientific, technical and medical information products and services, today announced a new version of its online research tool BrainNavigator.

6 Oct 2010

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.

6 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Scientists use directed light to cause arrhythmia in genetically modified mice

Scientists at the University of Bonn have altered cardiac muscle cells to make them controllable with light. They were thus able to use directed light to cause conditions such as arrhythmia in genetically modified mice. The method opens up completely new possibilities for researching the development of such arrhythmias. The study will be published in the upcoming edition of "Nature Methods".

5 Oct 2010

Researchers explore changes in brain regions to combat sleep apnea

According to the National Heart, Lung and Blood Institute, the average sleep apnea sufferer stops breathing and loses oxygen between five and 30 times a night. This lack of oxygen leads to a host of complications, including high blood pressure, vascular disease, an abnormal heart rhythm, or even a fatal cardiac event. Now, a team of University of Missouri researchers is exploring the changes in distinct brain regions that contribute to these symptoms in hopes of combating this common health issue.

5 Oct 2010

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Building on its worldwide reputation as a leader in neuroscience research, McGill University today joined with two leading Swiss research institutions - the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETHZ) - to enhance neuroscience research in a host of areas, in fields that include pain therapy, Alzheimer's disease, synapse modelling and repair, neuroimmunology and genetic mechanisms of brain diseases.

5 Oct 2010

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

New research shows how old people are when they first develop Parkinson's disease is one of many clues in how long they'll survive with the disease. The research is published in the October 5, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Family based treatment more effective than traditional individual-based therapy for anorexia nervosa

An anorexia nervosa treatment strategy that promotes parental involvement in restoring an adolescent to healthy weight and eating habits is more effective than traditional individual-based anorexia nervosa therapy, according to new research.

5 Oct 2010

Evotec enters multiple target drug discovery collaboration with Shionogi

Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets.

5 Oct 2010

AmeriCares, AstraZeneca enter commitment to expand breast cancer treatment in Cambodia

AmeriCares and AstraZeneca Pharmaceuticals have made a three-year commitment to expand early breast cancer detection and treatment in Cambodia in hopes of increasing survival rates.

5 Oct 2010

Elsevier launches new journal on neuroscience

Elsevier, a world-leading publisher of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new journal, Developmental Cognitive Neuroscience.

5 Oct 2010

Healthcare system does not take girls with autism or ADHD symptoms seriously

When girls with symptoms of autism or ADHD seek professional medical help, their problems are often played down or misinterpreted, and there is a real risk that they will not get the help or support they need. As such, more training is needed in this area, particularly in the public sector, reveals a thesis from the University of Gothenburg.

4 Oct 2010

Neuroscience News and Research

AstraZeneca provides free medicines to patients at Primary Care Center Pharmacy in Sacramento

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

New video PSA may help raise donation for brain research

Herbal supplements can treat anxiety disorders

Lumosity.com launches Italian version of cognitive training service

NBF's Brilliance in Bipolar Initiative receives Congressman Kennedy's endorsement

New hope for patients with brain injury

Study may lend insight about hallucination mechanism in schizophrenia

Elsevier launches new version of BrainNavigator online research tool

Watson seeks FDA approval to market rasagiline mesylate tablets

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Scientists use directed light to cause arrhythmia in genetically modified mice

Researchers explore changes in brain regions to combat sleep apnea

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

Family based treatment more effective than traditional individual-based therapy for anorexia nervosa

Evotec enters multiple target drug discovery collaboration with Shionogi

AmeriCares, AstraZeneca enter commitment to expand breast cancer treatment in Cambodia

Elsevier launches new journal on neuroscience

Healthcare system does not take girls with autism or ADHD symptoms seriously

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News